SCALP EG

SCALP EG
Name	SCALP EG
Purpose	Transcranial electrical stimulation system

SCALP EG

SCALP EG is a noninvasive transcranial stimulation platform used for therapeutic neuromodulation and diagnostic mapping that integrates electrical stimulation, electrophysiological recording, and algorithmic targeting. It combines hardware and software components influenced by developments from institutions and companies such as MIT, Harvard University, Stanford University, Massachusetts General Hospital, Johns Hopkins Hospital and University College London to deliver focal cortical modulation. Deployment contexts include academic research centers, clinical trial sites, neurorehabilitation clinics, and industry-sponsored studies associated with organizations like National Institutes of Health, Wellcome Trust, European Commission, Food and Drug Administration, and National Institute of Mental Health.

Overview

SCALP EG is presented as a multi-channel, programmable stimulator and recorder intended for focal scalp-based electrical field delivery with concurrent electroencephalographic monitoring and integration with neuronavigation systems from BrainLab, Brainsight, Medtronic, Siemens Healthineers and GE Healthcare. The device architecture references prior technologies developed at University of California, San Francisco, University of Pennsylvania, University of Oxford, Karolinska Institutet, University of Toronto, and McGill University. It supports standardized protocols used in collaborative multicenter studies funded by agencies such as European Research Council, Wellcome Trust, Medical Research Council (United Kingdom), and NIH BRAIN Initiative.

Technique and Protocol

SCALP EG employs multi-electrode montages that can be configured using finite element modeling informed by magnetic resonance imaging from Siemens Healthineers or Philips scanners and structural atlases including the Allen Brain Atlas. Targeting workflows often reference cortical parcellations by Brodmann, connectivity maps from projects like the Human Connectome Project, and stereotactic coordinates used in publications from Mayo Clinic, Cleveland Clinic, and Duke University Health System. Stimulation parameters (current intensity, waveform, duty cycle) are programmable within ranges used in trials at Columbia University, Yale School of Medicine, University of Michigan, and Northwestern University Feinberg School of Medicine. Protocol execution frequently leverages neuronavigation and neurophysiological endpoints validated in studies by Karolinska Institutet, University of Edinburgh, Imperial College London, and Johns Hopkins University.

Clinical Applications and Indications

SCALP EG has been investigated for indications including treatment-resistant depression studied at King's College London and Mount Sinai Health System, neuropathic pain researched at Mayo Clinic and Stanford University School of Medicine, post-stroke motor recovery trials conducted at University of Zurich and University of Pennsylvania Perelman School of Medicine, and cognitive enhancement experiments at Massachusetts Institute of Technology and University of Cambridge. Additional exploratory uses include tinnitus addressed in trials at University of Regensburg, epilepsy mapping and modulation trials at National Hospital for Neurology and Neurosurgery and UCL Queen Square Institute of Neurology, and Parkinsonian symptom modulation in studies linked to University College London Hospitals and University of California, San Diego.

Safety, Contraindications, and Side Effects

Safety frameworks for SCALP EG align with regulatory guidance from Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and standards committees including International Electrotechnical Commission and IEEE Standards Association. Contraindications considered in clinical protocols echo those used by American Academy of Neurology guidelines and institutional review boards at Johns Hopkins Hospital and Massachusetts General Hospital; examples include implanted electronic devices such as those by Medtronic and Boston Scientific, active intracranial pathology managed at Cleveland Clinic, and unstable medical conditions treated at Mayo Clinic. Reported side effects in trials at University of Oxford, Karolinska Institutet, and University of Toronto are generally transient and include scalp discomfort, paresthesia, and mild headache consistent with literature from Columbia University Irving Medical Center, Yale New Haven Hospital, and University of Michigan Health System.

Efficacy Evidence and Clinical Studies

Efficacy assessments for SCALP EG derive from randomized controlled trials, open-label studies, and mechanistic investigations conducted at centers such as Mount Sinai, Imperial College London, King's College London, Stanford Medicine, Harvard Medical School, University of Pennsylvania, University of California, Los Angeles, and University of Cambridge. Outcomes measured include mood scales used in Maudsley Hospital collaborations, motor scales validated at Kessler Foundation, neurophysiological metrics established by International Federation of Clinical Neurophysiology, and cognitive batteries from Neuropsychological Assessment Centers affiliated with Columbia University. Meta-analyses and systematic reviews by teams connected to Cochrane and BMJ Publishing Group contextualize effect sizes relative to sham-controlled paradigms.

Comparison with Alternative Modalities

SCALP EG is compared in head-to-head and parallel studies with modalities such as transcranial magnetic stimulation pioneered at National Institute of Mental Health, deep brain stimulation systems developed by Medtronic and Abbott Laboratories, direct current stimulation platforms from Soterix Medical and NeuroConn, and invasive cortical stimulation approaches used in Epilepsy Monitoring Units at Cleveland Clinic and Johns Hopkins Hospital. Comparative analyses reference clinical outcomes reported by research groups at Massachusetts General Hospital, Mayo Clinic, UCSF, Duke University, and Vanderbilt University Medical Center and technology evaluations by FDA panels, NICE committees, and academic consortia including the International Neuromodulation Society.

Category:Neuromodulation devices